Phenocell is a Partner Research Organization leading the way in iPSC technology to advance drug discovery in dermo-cosmetics and ophthalmology research. In the rapidly evolving field of biotechnology, Phenocell stands out for its innovation, dedication and expertise, using the Nobel Prize winning technology of Induced pluripotent stem cells (iPSC). At Phenocell, we combine the possibility to obtain human cells with controlled genetic background in unlimited number and a strong technological platform, to significantly accelerate your research and bring groundbreaking therapies to market faster.
Cutting-edge Human iPSC Solutions
Phenocell's core expertise lies in the development and utilization of human iPSC. These models are pivotal for understanding human biology and disease mechanisms, offering a more accurate representation of human physiological conditions compared to traditional cell lines or animal models. Phenocell’s iPSC-derived cells are used extensively to optimize early stages drug discoveries in various research applications, including drug screening, toxicology studies, and disease modeling.
Fight Retinal Degeneration: The Ophthalmology Platform
Age-related Macular Degeneration (AMD) is the leading cause of blindness in the elderly population, currently affecting around 200 million people worldwide. With an aging population, rates of AMD are predicted to increase by 44% by 2040. AMD is characterized by the progressive loss of central vision and can be split into two broad types: "wet" AMD (~10% of cases) and "dry" AMD, which accounts for around 90% of all AMD cases. Despite the dominant prevalence of dry AMD, there is currently no treatment.
To address this pressing need for dry AMD therapies, Phenocell offers a strong expertise with human iPSC-derived retinal pigment epithelium (RPE) models from healthy and AMD patient donors. The RPE plays a crucial role in the pathophysiology of dry AMD, its dysfunction and degeneration leading to drusen accumulation, photoreceptor damage, inflammation and oxidative stress, resulting in progressive vision loss. With our unique chronic N-retinylidene-N-retinylethanolamine (A2E) treatment combined with blue light irradiation, we closely reproduce pathological AMD conditions to produce more human-relevant AMD models.
Solutions to Skin Disorders: The Dermo-cosmetic Platform
Acne
Acne affects around 650 million people globally, with excess sebum production and inflammation being key factors. Phenocell leads acne research with its innovative iPSC-derived sebocyte model, which mimics normal sebocytes' functions, including sebum production, while ensuring high stability and reproducibility. Unlike traditional cell lines, these cells have a normal karyotype and provide a consistent, unlimited supply. Phenocell's platform supports high-throughput screening of pharmaceutical ingredients, aiding the discovery of new treatments. Our advanced bioassays, tailored to different ethnicities, cover various applications such as sebum production, inflammation response, and oxidative stress, facilitating efficient acne research and therapy development.
Pigmentation
Phenocell offers an advanced iPSC-derived melanocyte model for pigmentation research, providing a robust and reproducible tool for testing dermo-cosmetic ingredients. These cells retain key functional characteristics of normal melanocytes, such as melanin synthesis, and offer high genomic stability, making them ideal for high-throughput screening. With models derived from diverse ethnic backgrounds (African, Asian and Caucasian), Phenocell’s platform supports comprehensive bioassays, including melanogenesis pathway analysis, melanin content measurement, and oxidative stress testing. This innovative model accelerates the discovery and development of effective skincare solutions, ensuring precise and reliable results.
Comprehensive Drug Discovery Services
Phenocell offers a suite of services designed to support every stage of the drug discovery process, from initial screening to preclinical development.
High-Throughput Screening: Utilizing our robust stem cell technology, Phenocell provides high-throughput screening services to identify potential drug candidates. Our advanced screening platforms can evaluate hundreds of compounds simultaneously, accelerating the discovery of novel therapeutics.
Phenotypic Screening: Phenocell’s phenotypic screening services involve assessing the biological activity of compounds in disease-relevant cell models. This approach is particularly effective for identifying compounds that can modulate disease phenotypes, offering a powerful tool for discovering new treatments for complex diseases.
Toxicity Testing: Safety is paramount in drug development, and Phenocell offers comprehensive toxicity testing services. Our human cell models provide a more accurate prediction of how drugs will interact with human tissues, identifying potential toxic effects early in the development process.
Phenocell: Your Partner in Shaping the Future
Phenocell’s success is built on a foundation of collaboration. We work closely with academic institutions, biotechnology companies, and pharmaceutical firms to advance the dermo-cosmetic and ophthalmology fields. Recognizing that every research project is unique, Phenocell provides customized assay development services. Our team of experts will collaborate closely with you to design and implement assays tailored to your needs, ensuring optimal results.
For more information on how Phenocell can support your research and development efforts, visit our website and contact our team of experts. Together, we can shape the future of medicine and improve the lives of patients around the world.
About Drug Discovery Innovation Programme 2024
Drug Discovery Innovation Programme is an invitation-only and one of the best platforms to learn the latest insights and develop lasting business relationships.
This year’s Drug Discovery Innovation Programme will highlight the challenges discovery pipelines have faced due to COVID-19 and will put a spotlight on thec adoption of technology to finding the solutions.
With over 100+ attendees, learn how modernization in R&D processes is fundamentally changing what the drug discovery research will look like in the next two to five years.
So, join us in 2024 for an in-person experience and 2-days of top-level strategic content and the current scientific insights, networking, and discussions from leading global pharmaceutical R&D executives.
Companies in attendance for 2024 will include Servier Pharmaceuticals, Monte Rosa Therapeutics, University of Oxford, WPD Pharmaceuticals, AISA Therapeutics, Anima Biotech, PDC*line Pharma, Eli Lillly and Company, Symphogen, IRB Barcelona, Axonis Therapeutics, Genentech, Arakis Therapeutics, Johnson & Johnson, Amgen, Revitale Pharma, Progenra Inc, CERo Therapeutics, Merck and much more.